| Trial ID: | L1903 |
| Source ID: | NCT01526980
|
| Associated Drug: |
Biphasic Insulin Aspart 30
|
| Title: |
Glycaemic Control of Biphasic Insulin Aspart 70 and 30 in Subjects With Type 2 Diabetes
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Diabetes|Diabetes Mellitus, Type 2
|
| Interventions: |
DRUG: biphasic insulin aspart 30|DRUG: biphasic insulin aspart 70|DRUG: biphasic human insulin 30
|
| Outcome Measures: |
Primary: Glucose average in 24-hour blood glucose profiles | Secondary: Pre-meal glucose level|Post-meal excursion of glucose (0-4 hours)|Cmax, maximum concentration of total insulin|tmax, time of maximum concentration of total insulin|The area under the 24-hour total insulin concentration time curve|Adverse events
|
| Sponsor/Collaborators: |
Sponsor: Novo Nordisk A/S
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE2
|
| Enrollment: |
31
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: TREATMENT
|
| Start Date: |
2002-05
|
| Completion Date: |
2002-11
|
| Results First Posted: |
|
| Last Update Posted: |
2017-01-05
|
| Locations: |
Novo Nordisk Investigational Site, Newcastle, United Kingdom
|
| URL: |
https://clinicaltrials.gov/show/NCT01526980
|
